SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$809M
Q4 2018
Positions
24
Filings on Record
27
2019–present window
Filed
Feb 14, 2019
original filing

Summary

Boxer Capital, LLC reported $809M in U.S.-listed holdings across 24 positions for Q4 2018.

Its largest position, ONC, represents 15.6% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+80.4%
share of reported value
Largest Position
+15.6%
Beigene

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 47.1%Other: 37.3%ADR: 15.6%
  • Common Stock · 47.1% · $381M
  • Other · 37.3% · $302M
  • ADR · 15.6% · $126M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ONCBEIGENE LTDNEW+900.0K900.0K+$126M$126M
SOLID BIOSCIENCES INCNEW+3.50M3.50M+$94M$94M
PTCTPTC THERAPEUTICS INCNEW+2.15M2.15M+$74M$74M
WAVE LIFE SCIENCES LTDNEW+1.65M1.65M+$69M$69M
MRTXEURMIRATI THERAPEUTICS INCNEW+1.57M1.57M+$66M$66M
ICPTUSDINTERCEPT PHARMACEUTICALS INNEW+600.0K600.0K+$60M$60M
ESPRESPERION THERAPEUTICS INC NENEW+1.20M1.20M+$55M$55M
ODONATE THERAPEUTICS INCNEW+2.98M2.98M+$42M$42M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ONCBEIGENE LTDhistory →SPONSORED ADR15.60%$126M900.0K
2SOLID BIOSCIENCES INCCOM11.58%$94M3.50M
3PTCTPTC THERAPEUTICS INChistory →COM9.14%$74M2.15M
4WAVE LIFE SCIENCES LTDSHS8.57%$69M1.65M
5MRTXEURMIRATI THERAPEUTICS INChistory →COM8.21%$66M1.57M
6ICPTUSDINTERCEPT PHARMACEUTICALS INhistory →COM7.47%$60M600.0K
7ESPRESPERION THERAPEUTICS INC NEhistory →COM6.82%$55M1.20M
8ODONATE THERAPEUTICS INCCOM5.18%$42M2.98M
9UNIQURE NVSHS4.27%$35M1.20M
10RCKTROCKET PHARMACEUTICALS INChistory →COM3.60%$29M1.97M
11DBV TECHNOLOGIES S ASPONSORED ADR3.57%$29M4.50M
12GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM3.55%$29M700.0K
13AMARIN CORP PLCSPONS ADR NEW2.52%$20M1.50M
14CYMABAY THERAPEUTICS INCCOM2.04%$16M2.09M
15IMMUIMMUNOMEDICS INChistory →COM2.03%$16M1.15M
16KURAKURA ONCOLOGY INChistory →COM1.47%$12M844.8K
17KINIKSA PHARMACEUTICALS LTDCOM CL A1.01%$8M290.6K
18MEI PHARMA INCCOM NEW0.95%$8M2.91M
19MDCOUSDMEDICINES COCOM0.55%$4M232.0K
204XC1KALVISTA PHARMACEUTICALS INCCOM0.49%$4M200.0K
21MTNBEURMATINAS BIOPHARMA HLDGS INCCOM0.41%$3M5.64M
22RETAEURREATA PHARMACEUTICALS INCCL A0.35%$3M50.0K
23TKAIEURNOVUS THERAPEUTICS INCCOM0.06%$519,000324.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.